Autologous Stem Cell Therapy Development for the Brain

Regeneration Biomedical, Inc., of Newport Beach, CA, leverages world-class capabilities in stem cell therapy development and clinical application. Our research focuses on Alzheimer’s Disease, ALS, Multiple Sclerosis, Parkinson’s disease and its variants, stroke, and traumatic brain injury (including chronic traumatic encephalopathy (CTE). Because all of these diseases are neurodegenerative, the best way to attack them is by injecting stem cells directly into the brain. The technique we developed places the stem cells where we think they need to be, to achieve the ultimate efficacy. We are seeking private, VC, and corporate funding for moving into Phase 1/2 FDA trials for these deadly diseases with no current curative therapies.

Company Overview


Our company is at the forefront of the biomedical research industry thanks to professionals who have had more than 30 years of medical and research experience.


We believe that a patient’s OWN stem cells (autologous) have the power to heal. Other stem cell technologies are using umbilical, fetal, embryonic and other allogeneic cells (from other donors or banks), which in and of themselves have…


Our proprietary therapy is derived from a patient’s own fat cells, which is a First-in-Class Adipose-Derived Stem Cell population. We use a proprietary isolation-expansion-enrichment manufacturing protocol to synthesize the therapy and inject it directly into the brain.

Past Research

Our preliminary work was essentially a Phase 1 safety trial in humans performed with IRB approval. We were not looking for clinical efficacy. However, secondary endpoints such as improvement in their conditions were certainly optimistic and have acted…

FDA Clinical Trials

After two years of diligent collaboration with the FDA (conducting a requested large animal safety study, presenting them with all of our past IRB approved human trial work, meeting all of their requirements, and satisfying all of their questions), Regeneration Biomedical received clearance to begin our Phase 1 Safety Trial of our product CEREWINT. Our Phase 1 Safety Trial will be conducted at Hoag Hospital Newport Beach. To view the trial details click here.

CEREWiNT® Phase 1 Clinical Safety Trial

About Us

Founder Christopher Duma, MD, FACS and his advisor Hans Keirstead, PhD have been doing human pre-clinical work for this endeavor for 5 years. However, Dr. Duma has 30 years of brain surgery experience and Dr. Keirstead has 30 years of stem cell research experience. From the start, Dr. Duma’s goal was to develop a technique for injecting stem cells directly into the brain. His cell preparation and injection technique is patent pending.

(877) 240-1660

“Modern medical advances have helped millions of people live longer, healthier lives. We owe these improvements to decades of investment in medical research.”

Ike Skelton

Investment Opportunities

Venture into the biomedical research market or extend your reach into it by investing in RBI, Inc. Your funding will help us continue making inroads into the field of stem cell research and treatments. Contact us for additional details about investing.

The global center nervous system therapeutic market was worth USD 77.2 billion in 2016 and is anticipated to grow at a CAGR of 5.9%


Thank you for your interest. We look forward to hearing from you soon.

Go to Top